Myeloma UK funded research supports the need for molecular analysis at relapse

Myeloma UK funded research recently published in Leukemia shows that acquisition of new copy number aberrations is associated with relapse and therefore strongly supports the need for repeated molecular analysis at relapse. Chromosomal changes like copy number aberrations (structural amplifications, gains, or deletions) are a feature of myeloma. However, the relationship between copy number aberrations…

Double accreditation for Myeloma UK patient services

In the last couple of months, Myeloma UK has received two professional accreditations for their patient services. In November, the Myeloma Information Specialist Team received the Helplines Standard accreditation from The Helplines Partnership for the sixteenth year running. The Helplines Standard is a nationally recognized quality standard which defines and recognizes best practice in helpline…

GP Myeloma Diagnostic Tool

Early diagnosis of myeloma relies on primary care clinicians being able to accurately suspect, test and refer patients with suspected myeloma. It is important that GPs are able to distinguish those patients that require urgent investigation in secondary care versus those that likely have lower risk MGUS and so can be monitored in primary care or via discussion…

An update on potential new myeloma treatments in 2020

The year so far has been particularly busy for the myeloma access pipeline with four new myeloma treatments being appraised by both drug approval bodies, the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC). There is also a new treatment for patients with AL Amyloidosis which has begun the appraisal process…

Myeloma UK launches Digital Infoday Sessions

Myeloma UK have developed a series of Digital Infoday Sessions to continue providing information and support to patients following the cancellation of our usual Infoday events programme. The online events take place in a variety of formats, each lasting one hour. This includes panel discussions, Q & A sessions and presentations each centred around a…

Guidelines for the diagnosis and management of multiple myeloma 2013 – management and treatment

These updated guidelines, produced by the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum, summarise a national consensus of the haematological community involved in the diagnosis and management of myeloma patients. They should be read in conjunction with the BCSH Guidelines on the supportive care of myeloma patients. Bird et al.…